东瑞制药(02348.HK)向康方生物(09926.HK)悉售创新药物产品研发合资35%股权

阿斯达克财经02-09

东瑞制药(02348.HK) 公布，其全资附属东瑞生物向康方生物(09926.HK) 的全资附属中山康方，悉售东瑞生物于康融东方的35%股权，购买价为2.67亿元人民币(下同)。该协议亦要求康融东方偿还无抵押贷款及截至昨日(8日)的应计利息。于昨日，上述无抵押贷款的未偿还本金总额为1.16亿元。因此，东瑞生物根据该协议有权收取合共3.9亿元。东瑞制药估计出售事项将确认税前收益净额约2.67亿至...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2410774772?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190723164448759_s.jpg","is_english":false,"pubTime":"2024-02-09 08:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2410774772","market":"hk","top_or_hot":-1,"title":"东瑞制药(02348.HK)向康方生物(09926.HK)悉售创新药物产品研发合资35%股权","media":"阿斯达克财经","content":"<div>\n<p>东瑞制药(02348.HK) 公布，其全资附属东瑞生物向康方生物(09926.HK) 的全资附属中山康方，悉售东瑞生物于康融东方的35%股权，购买价为2.67亿元人民币(下同)。该协议亦要求康融东方偿还无抵押贷款及截至昨日(8日)的应计利息。于昨日，上述无抵押贷款的未偿还本金总额为1.16亿元。因此，东瑞生物根据该协议有权收取合共3.9亿元。东瑞制药估计出售事项将确认税前收益净额约2.67亿至...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1325977/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>东瑞制药(02348.HK)向康方生物(09926.HK)悉售创新药物产品研发合资35%股权</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n东瑞制药(02348.HK)向康方生物(09926.HK)悉售创新药物产品研发合资35%股权\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-09 08:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1325977/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>东瑞制药(02348.HK) 公布，其全资附属东瑞生物向康方生物(09926.HK) 的全资附属中山康方，悉售东瑞生物于康融东方的35%股权，购买价为2.67亿元人民币(下同)。该协议亦要求康融东方偿还无抵押贷款及截至昨日(8日)的应计利息。于昨日，上述无抵押贷款的未偿还本金总额为1.16亿元。因此，东瑞生物根据该协议有权收取合共3.9亿元。东瑞制药估计出售事项将确认税前收益净额约2.67亿至...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1325977/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1325977/latest-news/AAFN","article_id":"2410774772","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190723164448759_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2410774772","pubTimestamp":1707438780,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"东瑞制药公布，其全资附属东瑞生物向康方生物的全资附属中山康方，悉售东瑞生物于康融东方的35%股权，购买价为2.67亿元人民币(下同)。因此，东瑞生物根据该协议有权收取合共3.9亿元。东瑞制药估计出售事项将确认税前收益净额约2.67亿至2.85亿元，出售所得资源将用于研发项目以及制造及销售活动。康方生物认为，将康融东方创新药物产品全面融入公司旗下肿瘤和非肿瘤产品管线，将有利于该两款产品后续临床开发及商业计划的整体高效运作。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","09926":"康方生物","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","BK1574":"生物医药B类股","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","02348":"东瑞制药","BK1161":"生物科技","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU1720050803.USD":"安联全方位中国股票基金","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","06978":"永泰生物-B","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","BK1191":"制药"},"translate_title":"Dongrui Pharmaceutical (02348. HK) sold 35% equity of innovative drug product research and development joint venture to Kangfang Bio (09926. HK)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"02348":1,"06978":1,"09926":1},"content_text":"东瑞制药(02348.HK) 公布，其全资附属东瑞生物向康方生物(09926.HK) 的全资附属中山康方，悉售东瑞生物于康融东方的35%股权，购买价为2.67亿元人民币(下同)。该协议亦要求康融东方偿还无抵押贷款及截至昨日(8日)的应计利息。于昨日，上述无抵押贷款的未偿还本金总额为1.16亿元。因此，东瑞生物根据该协议有权收取合共3.9亿元。东瑞制药估计出售事项将确认税前收益净额约2.67亿至2.85亿元，出售所得资源将用于研发项目以及制造及销售活动。康融东方为康方生物与东瑞制药于2017年成立的合营企业，主要从事创新药物产品研发，包括已于2023年6月提交新药上市申请的用于治疗代谢类疾病的一类新药伊努西单抗(AK102，PCSK9单抗)及正处于II期临床试验的用于晚期实体肿瘤治疗的一类新药普络西单抗(AK109，VEGFR-2单抗)。康方生物认为，将康融东方创新药物产品全面融入公司旗下肿瘤和非肿瘤产品管线，将有利于该两款产品后续临床开发及商业计划的整体高效运作。公司将从未来商业化发展、产能利用等方面进行整体规划与安排，充分发挥在研发、生产和商业化的成本与协同效应的优势。(jl/cy)(港股报价延迟最少十五分钟。沽空资料截至 2024-02-08 16:25。)AASTOCKS新闻","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2410774772"}